Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year?
Here is how ANIXA BIOSCIENCES INC (ANIX) and DBV Technologies S.A. (DBVT) have performed compared to their sector so far this year.
Anixa Biosciences to Host an Investor Webcast on June 26, 2025
SAN JOSE, Calif. , June 20, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will host an investor webcast presentation on June 26, 2025 at 2:00 PM EDT.
What Makes ANIXA BIOSCIENCES INC (ANIX) a Strong Momentum Stock: Buy Now?
Does ANIXA BIOSCIENCES INC (ANIX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage
SAN JOSE, Calif. , June 10, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its CEO, Dr. Amit Kumar, was interviewed by the New York Post to discuss Anixa's breast cancer vaccine, and the breast cancer vaccine was featured on Fox News' "Fox & Friends.
All You Need to Know About Anixa Biosciences (ANIX) Rating Upgrade to Buy
Anixa Biosciences (ANIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year?
Here is how ANIXA BIOSCIENCES INC (ANIX) and Cellectar Biosciences, Inc. (CLRB) have performed compared to their sector so far this year.
Anixa Biosciences' Breast Cancer Vaccine Featured in NewsNation Interview
SAN JOSE, Calif. , June 3, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its CEO, Dr. Amit Kumar, was interviewed on NewsNation's "Elizabeth Vargas Reports" to discuss Anixa's breast cancer vaccine.
Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine
SAN JOSE, Calif. , June 2, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the completion of enrollment in the Phase 1 clinical trial of its breast cancer vaccine.
Anixa Biosciences CEO Provides Letter to Shareholders Outlining Significant Progress and Advancement Towards Potentially Transformative Milestones
SAN JOSE, Calif. , May 19, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today released a letter to shareholders from Chairman and CEO Dr. Amit Kumar, detailing significant progress across its programs and outlining key milestones for the remainder of the year.
Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th
SAN JOSE, Calif. , April 30, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced its participation in the H.C.
ANIX Gets New Patent for Breast Cancer Vaccine Technology, Stock Up
Anixa Biosciences stock jumps 13% on new patent grant for its breast cancer vaccine technology in the United States.
Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology
Patent Broadens Immunogenic Compositions for Preventive Vaccine Approach SAN JOSE, Calif. , April 9, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a new patent related to the Company's innovative breast cancer vaccine technology.
